Everything below concerns synthetic peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-23. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Mass analyzers separate the ions according to their mass-to-charge ratio. There are many types of mass analyzers, using either static or dynamic fields, magnetic or electric fields. Each analyzer type has its strengths and weaknesses. Many mass spectrometers use two or more mass analyzers for tandem mass spectrometry (MS/MS). In addition to the more common mass analyzers listed below, there are others designed for special situations.
Both religions revere John the Baptist, Saint George, and Elijah. Druze, believe that Elijah came back as John the Baptist, or as Saint George, since they belief in reincarnation and the transmigration of the soul, Druze believe that El Khidr and John the Baptist and Saint George are one and the same. Elijah is a central figure of Druzism, and he considered patron of the Druze people. Due to the Christian influence on the Druze faith, two Christian saints become the Druze's favorite venerated figures: Saint George and the Prophet Elijah. Thus, in all the villages inhabited by the Druze and Christians in central Mount Lebanon, a Christian church or Druze maqam is dedicated to either the Prophet Elijah or Saint George. The reverence for Saint George, who is often identified with Al-Khidr, is deeply integrated into various aspects of Druze culture and religious practices. According to scholar Ray Jabre Mouawad, the Druze appreciated the two saints for their bravery, Saint George because he confronted the dragon and the Prophet Elijah because he competed with the pagan priests of Baal and won over them. In both cases the explanations provided by Christians are that Druzes were attracted to warrior saints that resemble their own militarized society. The Druze environment influenced in turn the Christians, and Christians living among Druze started to adopt the same word for some of their churches, using maqām instead of kanīsah (church). Saint George is seen as a guardian of the Druze community and a symbol of their enduring faith and resilience.
The origin of cells has to do with the origin of life, which began the history of life on Earth. Small molecules needed for life may have been carried to Earth on meteorites, created at deep-sea hydrothermal vents, or synthesized by lightning in a reducing atmosphere. There is little experimental data defining what the first self-replicating forms were. RNA may have been the earliest self-replicating molecule, as it can both store genetic information and catalyze chemical reactions. This process required an enzyme to catalyze the RNA reactions, which may have been the early peptides that formed in hydrothermal vents. Cells emerged around 4 billion years ago. The first cells were most likely heterotrophs. The early cell membranes were probably simpler and more permeable than later ones, with only a single fatty acid chain per lipid. Lipids spontaneously form bilayered vesicles in water, and could have preceded RNA.
Sources: en.wikipedia.org
Chief Operating Officer Scott Boatwright was appointed by the board as interim CEO effective August 31, 2024. At the same board meeting, company director Scott Maw was named chairman of the board and retiring CFO Jack Hartung was named president. Four months later, Boatwright was named permanent CEO by the board in November 2024. Chipotle's key management as of January 2026 consists of:
Katopodis AG, Ping D, May SW (1990). "A novel enzyme from bovine neurointermediate pituitary catalyzes dealkylation of α-hydroxyglycine derivatives, thereby functioning sequentially with peptidylglycine α-amidating monooxygenase in peptide amidation". Biochemistry. 29 (26): 6115–20. doi:10.1021/bi00478a001. PMID 2207061.
Aldo Carl Leopold (December 18, 1919 – November 18, 2009) was an American academic and plant physiologist, son of Aldo Leopold, a noted ecologist. He is known for his research on soybeans which led to techniques allowing insulin to be dried and later processed into an inhalable insulin. Aldo Carl Leopold was born to Aldo Leopold, a noted ecologist and employee of the United States Forest Service, and Estella Leopold in Albuquerque, New Mexico as the 4th of 5 children.
== Bibliography == Atwood, David A. (2013). Radionuclides in the Environment. John Wiley and Sons. ISBN 978-1-118-63269-7. Emsley, John (2011). Nature's Building Blocks: An A-Z Guide to the Elements. New York: Oxford University Press, USA. ISBN 978-0-199-60563-7. Hoffman, Klaus (2001). Otto Hahn: Achievement and Responsibility. Springer. Bibcode:2002ohar.book.....H. ISBN 978-0-387-95057-0. Lemire, Robert J. (2001). Chemical Thermodynamics of Neptunium and Plutonium. Amsterdam: Elsevier. ISBN 978-0-444-50379-4. Rhodes, Richard (2012). The Making of the Atomic Bomb (25th Anniversary ed.). New York: Simon & Schuster. ISBN 978-1-451-67761-4. Yoshida, Zenko; Johnson, Stephen G.; Kimura, Takaumi; Krsul, John R. (2006). "Neptunium". In Morss, Lester R.; Edelstein, Norman M.; Fuger, Jean (eds.). The Chemistry of the Actinide and Transactinide Elements (PDF). Vol. 3 (3rd ed.). Dordrecht, the Netherlands: Springer. pp. 699–812. doi:10.1007/1-4020-3598-5_6. ISBN 978-1-4020-3555-5. Archived from the original (PDF) on January 17, 2018.
Sources: en.wikipedia.org
In July 2020, BK announced it would begin selling a Whopper patty made from cows on a low methane diet. In late 2021 and early 2022, the company announced it would cut back on value items and altered product configuration because of inflationary pressures and to speed up drive-thru lanes. After successfully testing vegan products at meat-free temporary restaurants in Leicester Square and Bristol, Burger King UK announced that in 2023 it would offer a Vegan Royale Bakon King, made with vegan bacon, vegan cheese and a vegan burger made by The Vegetarian Butcher.
==== Aerobic ==== Aerobic exercise for fibromyalgia patients is the most investigated type of exercise. It includes activities such as walking, jogging, spinning, cycling, dancing and exercising in water, with walking being named as one of the best methods. A 2017 Cochrane summary concluded that aerobic exercise probably improves quality of life, slightly decreases pain and improves physical function and makes no difference in fatigue and stiffness. A 2019 meta-analysis showed that exercising aerobically can reduce autonomic dysfunction and increase heart rate variability. This happens when patients exercise at least twice a week, for 45–60 minutes at about 60%–80% of the maximum heart rate. Aerobic exercise also decreases anxiety and depression, and improves the quality of life. Exercising aerobically 2–3 times a week has been shown to alleviate pain.
In contrast with gases, there is no simple yet accurate picture for the molecular origins of viscosity in liquids. At the simplest level of description, the relative motion of adjacent layers in a liquid is opposed primarily by attractive molecular forces acting across the layer boundary. In this picture, one (correctly) expects viscosity to decrease with increasing temperature. This is because increasing temperature increases the random thermal motion of the molecules, which makes it easier for them to overcome their attractive interactions. Building on this visualization, a simple theory can be constructed in analogy with the discrete structure of a solid: groups of molecules in a liquid are visualized as forming "cages" which surround and enclose single molecules. These cages can be occupied or unoccupied, and stronger molecular attraction corresponds to stronger cages. Due to random thermal motion, a molecule "hops" between cages at a rate which varies inversely with the strength of molecular attractions. In equilibrium these "hops" are not biased in any direction. On the other hand, in order for two adjacent layers to move relative to each other, the "hops" must be biased in the direction of the relative motion. The force required to sustain this directed motion can be estimated for a given shear rate, leading to
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.